China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
000999
Rangering i aksjer
#2914
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent... China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent pharmaceutical enterprise engaged in the research, development, manufacturing, and distribution of medicinal products. Its operations span both the People's Republic of China and international markets, additionally providing various health-related services. The company's extensive product line includes a wide range of over-the-counter (OTC) medications addressing common conditions such as colds, skin issues, gastrointestinal complaints, coughs, and needs in orthopedics and pediatrics. It also provides prescription drugs, with a focus on areas like traditional Chinese medicine, oncology, cardiovascular and cerebrovascular health, digestive system disorders, orthopedics, and pediatrics. Further offerings comprise Chinese medicine injections, specialized formula granules, and anti-infective agents. These products are often marketed under popular brand families, notably 999 family medicine, Sanjiuweitai series, 999 Ganmaoling series, and 999 dermatitis series. Founded in 1999 and headquartered in Shenzhen, PRC, the company initially operated as Sanjiu Pharmaceutical Co., Ltd. before rebranding to its current name in February 2010. It functions as a subsidiary under the umbrella of China Resources (Holdings) Co., Ltd.
Aksjekurs
$3.74
Markedsverdi
$6.23B
Endring (1 dag)
-2.11%
Endring (1 år)
-8.54%
Land
CN
Handel China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999)
Kategori
Healthcare
P/E-forhold for China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999)
P/E-forhold per October 2026 TTM: 12.63
Ifølge China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 12.63. Ved slutten av 2024 hadde selskapet en P/E på 16.86.
P/E-forholdshistorikk for China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. fra 2001 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 12.63 | -8.64% |
| 2025 | 13.82 | -18.06% |
| 2024 | 16.86 | -6.37% |
| 2023 | 18.01 | -4.60% |
| 2022 | 18.88 | 15.77% |
| 2021 | 16.30 | 6.54% |
| 2020 | 15.30 | 3.35% |
| 2019 | 14.81 | -11.72% |
| 2018 | 16.77 | -17.96% |
| 2017 | 20.44 | 0.88% |
| 2016 | 20.27 | -4.96% |
| 2015 | 21.32 | -0.27% |
| 2014 | 21.38 | 35.11% |
| 2013 | 15.83 | 17.39% |
| 2012 | 13.48 | -21.01% |
| 2011 | 17.07 | -27.93% |
| 2010 | 23.68 | 11.06% |
| 2009 | 21.32 | -1.85% |
| 2008 | 21.72 | -55.50% |
| 2007 | 48.82 | 80.27% |
| 2006 | 27.08 | 71.28% |
| 2005 | 15.81 | -693.03% |
| 2004 | -2.67 | -128.97% |
| 2003 | 9.20 | -20.97% |
| 2002 | 11.65 | -26.66% |
| 2001 | 15.88 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 23.30 | 84.53% |
DE
|
|
| 26.92 | 113.19% |
DE
|
|
| 55.58 | 340.17% |
JP
|
|
| 61.13 | 384.17% |
CH
|
|
| 34.87 | 176.20% |
IN
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.